1. Skye Bioscience faces a class action lawsuit for securities law violations. 2. Claims include false statements about nimacimab's efficacy during a specified period. 3. Shareholders can join case but lead plaintiff status isn't required. 4. Class period for claims extends from November 2024 to October 2025. 5. Investors urged to register before January 16, 2026, for participation.
FAQ
Why Very Bearish?
The lawsuit signals potential regulatory and financial risks, similar to past high-profile cases affecting stock values significantly.
How important is it?
The pending lawsuit indicates serious legal challenges for SKYE, which likely affects investor confidence significantly.
Why Short Term?
Immediate investor sentiment likely to decline due to legal uncertainties, with potential long-term effects depending on resolution.
LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye " or "the Company") (NASDAQ: SKYE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 4, 2024 to October 3, 2025
DEADLINE: January 16, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Skye's nimacimab failed to demonstrate the efficacy it had previously claimed. Based on these facts, Skye's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate .
NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/skye-bioscience-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--skye-302634942.html
SOURCE DJS Law Group LLP